FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891605364> ?p ?o ?g. }

• W2891605364 endingPage "83" @default.
• W2891605364 startingPage "70" @default.
• W2891605364 abstract "Type 2 diabetes is a debilitating disease that impacts the life expectancy, quality of life, and health of an individual. Cardiovascular disease (CVD) is a common diabetes-associated complication and a principal cause for death in diabetic patients. This review aims to investigate and summarize the effect of Type 2 diabetes mellitus (T2DM) medications on CVD issues. A comprehensive literature review mainly from level 1 evidence was performed. Thirty-seven articles were extracted from Google Scholar, ScienceDirect, ProQuest, and PubMed Database using a combination of keywords. The findings suggest that different glucose-lowering agents have been tested for their efficacy and safety in T2DM with CVD. Some of the recent trials such as the United Kingdom Prospective Diabetes Study, Empagliflozin (EMPA) Cardiovascular (CV) Outcome Event Trial in T2DM Patients-Removing Excess Glucose (EMPA-REG OUTCOME), Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results, and Trial to Evaluate CV and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN6) have shed important light on this vital clinical concern, thus demonstrating a convincing effect of liraglutide, semaglutide, and EMPA on CVD outcomes, while metformin is thought to be the first-line optimal oral agent to manage Type 2 diabetics. Some classes of drugs demonstrate CV protection, some of them may be a result of a class effect, and some differences might be based on the population enrolled individually. Most of the trials failed to show a significant benefit with regard to mortality and morbidity in spite of intensive glycemic control. This study, therefore, enabled us to develop a guide of potential antidiabetic medication that can influence or promote CV health. Health professionals in future should weigh the CV risk against possible advantages while prescribing antidiabetic medications." @default.
• W2891605364 created "2018-09-27" @default.
• W2891605364 creator A5081688173 @default.
• W2891605364 date "2018-09-12" @default.
• W2891605364 modified "2023-09-23" @default.
• W2891605364 title "Cardiovascular outcomes and safety with antidiabetic drugs." @default.
• W2891605364 cites W1774706564 @default.
• W2891605364 cites W1855278889 @default.
• W2891605364 cites W1879369255 @default.
• W2891605364 cites W1964957922 @default.
• W2891605364 cites W1975663485 @default.
• W2891605364 cites W1993112342 @default.
• W2891605364 cites W1997683054 @default.
• W2891605364 cites W2004409060 @default.
• W2891605364 cites W2004870840 @default.
• W2891605364 cites W2005088542 @default.
• W2891605364 cites W2011419875 @default.
• W2891605364 cites W2028581236 @default.
• W2891605364 cites W2036873878 @default.
• W2891605364 cites W2040493457 @default.
• W2891605364 cites W2064130493 @default.
• W2891605364 cites W2081276121 @default.
• W2891605364 cites W2087682588 @default.
• W2891605364 cites W2090102533 @default.
• W2891605364 cites W2100774365 @default.
• W2891605364 cites W2104961495 @default.
• W2891605364 cites W2105407506 @default.
• W2891605364 cites W2106895780 @default.
• W2891605364 cites W2126477578 @default.
• W2891605364 cites W2127125241 @default.
• W2891605364 cites W2127854619 @default.
• W2891605364 cites W2131490500 @default.
• W2891605364 cites W2141537593 @default.
• W2891605364 cites W2142830692 @default.
• W2891605364 cites W2146264128 @default.
• W2891605364 cites W2150180487 @default.
• W2891605364 cites W2159969745 @default.
• W2891605364 cites W2160088494 @default.
• W2891605364 cites W2162891101 @default.
• W2891605364 cites W2205010449 @default.
• W2891605364 cites W2271771390 @default.
• W2891605364 cites W2282578582 @default.
• W2891605364 cites W2329612550 @default.
• W2891605364 cites W2336957377 @default.
• W2891605364 cites W2346937144 @default.
• W2891605364 cites W2425644022 @default.
• W2891605364 cites W2519510391 @default.
• W2891605364 cites W2626446274 @default.
• W2891605364 cites W2754041380 @default.
• W2891605364 cites W2756152366 @default.
• W2891605364 cites W4210328094 @default.
• W2891605364 cites W960201800 @default.
• W2891605364 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6124835" @default.
• W2891605364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30202411" @default.
• W2891605364 hasPublicationYear "2018" @default.
• W2891605364 type Work @default.
• W2891605364 sameAs 2891605364 @default.
• W2891605364 citedByCount "4" @default.
• W2891605364 countsByYear W28916053642018 @default.
• W2891605364 countsByYear W28916053642019 @default.
• W2891605364 countsByYear W28916053642022 @default.
• W2891605364 countsByYear W28916053642023 @default.
• W2891605364 crossrefType "journal-article" @default.
• W2891605364 hasAuthorship W2891605364A5081688173 @default.
• W2891605364 hasConcept C126322002 @default.
• W2891605364 hasConcept C134018914 @default.
• W2891605364 hasConcept C177713679 @default.
• W2891605364 hasConcept C2775887513 @default.
• W2891605364 hasConcept C2777180221 @default.
• W2891605364 hasConcept C2779134260 @default.
• W2891605364 hasConcept C2780323712 @default.
• W2891605364 hasConcept C2780473172 @default.
• W2891605364 hasConcept C2780920962 @default.
• W2891605364 hasConcept C2781308992 @default.
• W2891605364 hasConcept C2908647359 @default.
• W2891605364 hasConcept C2909862629 @default.
• W2891605364 hasConcept C2910068830 @default.
• W2891605364 hasConcept C555293320 @default.
• W2891605364 hasConcept C71924100 @default.
• W2891605364 hasConcept C99454951 @default.
• W2891605364 hasConceptScore W2891605364C126322002 @default.
• W2891605364 hasConceptScore W2891605364C134018914 @default.
• W2891605364 hasConceptScore W2891605364C177713679 @default.
• W2891605364 hasConceptScore W2891605364C2775887513 @default.
• W2891605364 hasConceptScore W2891605364C2777180221 @default.
• W2891605364 hasConceptScore W2891605364C2779134260 @default.
• W2891605364 hasConceptScore W2891605364C2780323712 @default.
• W2891605364 hasConceptScore W2891605364C2780473172 @default.
• W2891605364 hasConceptScore W2891605364C2780920962 @default.
• W2891605364 hasConceptScore W2891605364C2781308992 @default.
• W2891605364 hasConceptScore W2891605364C2908647359 @default.
• W2891605364 hasConceptScore W2891605364C2909862629 @default.
• W2891605364 hasConceptScore W2891605364C2910068830 @default.
• W2891605364 hasConceptScore W2891605364C555293320 @default.
• W2891605364 hasConceptScore W2891605364C71924100 @default.
• W2891605364 hasConceptScore W2891605364C99454951 @default.
• W2891605364 hasIssue "5" @default.
• W2891605364 hasLocation W28916053641 @default.

• next